Beam Therapeutics (BEAM) Non-Current Assets (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Non-Current Assets data on file, last reported at $213.8 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $213.8 million, down 2.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $854.6 million (down 5.33% YoY), and the FY2025 annual result was $212.5 million, down 5.84% from the prior year.
• Non-Current Assets improved to $213.8 million in Q1 2026 per BEAM's latest filing, from $212.5 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $259.1 million in Q2 2023 and troughed at $212.5 million in Q4 2025.
• A 5-year average of $232.1 million and a median of $231.8 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets grew 23.52% in 2022, then declined 10.52% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $248.8 million in 2022, then dropped by 0.06% to $248.7 million in 2023, then decreased by 9.25% to $225.7 million in 2024, then decreased by 5.84% to $212.5 million in 2025, then increased by 0.64% to $213.8 million in 2026.
• Business Quant data shows BEAM's Non-Current Assets at $213.8 million in Q1 2026, $212.5 million in Q4 2025, and $212.5 million in Q3 2025.